Skip to content

Prospective Clinical Study of Intraoperative Assessment of Resection Margin of Colo-Rectal Cancer Liver Metastases

Prospective Clinical Study of Intraoperative Assessment of Resection Margin of Colo-Rectal Cancer Liver Metastases

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04634526
Enrollment
250
Registered
2020-11-18
Start date
2018-04-18
Completion date
2026-01-01
Last updated
2020-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Metastasis Colon Cancer

Brief summary

This prospective single arm double-blind study approved by the Ethics Committee of the institution, will be conducted on at the Oncology Institute of Vojvodina in Sremska Kamenica, Serbia. Patients with colo-rectal cancer liver metastases (CRLM) is presented to the multi-disciplinary team (MDT).Screening and enrolment is conducted after established of indication for resection. The surgeons assesses resection margin (RM) for every resected liver specimen (RLS) intra-operatively by inspection and palpation. These data will be compared with pathological RM examination as a gold standard. Resection margin of 1 mm or more will be rated as negative RM (RM-) otherwise RM is positive (RM+). Taking the result of the pathohistological examination as gold standard it is determined that RM is true positive when the pathologist and surgeon agreed that the RM is positive. False negative RM is when the surgeon assesses RM as negative and pathologist as positive. The sensitivity of the surgical assessment of RM+ is defined as the rate of RM+ which was correctly identified. True negative RM is determined when the pathologist and surgeon agreed that it is negative RM. False positive RM defined when the surgeon assessed RM as positive, but pathologist found that it was RM-. The specificity of the surgical assessment of RM is defined as the rate of RM- which is correctly identified. Total accuracy represents the rate of correctly recognized positive and negative RM, relative to the total number of samples. Agreement between surgeon and pathologists finding will be analyzed as well as difference between them. Disease recurrence and disease-free survival (DFS) will be analyzed by RM.

Interventions

None listed

Sponsors

Oncology Institute of Vojvodina
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years

Inclusion criteria

* Older than 18 years * Preoperative diagnosis of liver metastases of colorectal adenocarcinoma * Indication for surgical resection of liver metastases of colorectal adenocarcinoma

Exclusion criteria

* RM is not defined by surgeons and pathologists as positive or negative * Surgical resections and application of ablative procedures at the same time * Surgery for relapse of CRLM, if the first CRLM surgery is performed before this study start * Resection was not done from any reason

Design outcomes

Primary

MeasureTime frameDescription
Rate of R1 cases assessed by surgeonat the operationResection margin defined by surgeon could be negative (R0), positive without residual tumor (R1) and positive with residual tumor (R2)

Secondary

MeasureTime frameDescription
Recurrence rateup to 5-yearsPercentage of patients with recurrence of disease
Disease free survivalup to 5-yearsTime period from operation to the disease recurrence

Countries

Serbia

Contacts

Primary ContactMladjan Protic, MD,PhD
mlprotic@gmail.com+381641253308

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026